Crossmark

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

Crossref DOI link: https://doi.org/10.1007/s00262-025-04125-w

Published Online: 2025-07-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Inno, Alessandro

Veccia, Antonello

D’Argento, Ettore

Morgillo, Floriana

Pizzutilo, Elio Gregory

Vitiello, Fabiana

Pavan, Alberto

Lombardo, Fiorella

Russano, Marco

Sforza, Vincenzo

Colamartini, Francesca

Genova, Carlo

Chiari, Rita

Cristofano, Antonella

Delconte, Alessandro

Vattemi, Emanuela

Dessi, Alessandra

Galanti, Daniele

Busato, Simona

Palazzolo, Giovanni

Savastano, Clementina

Bianco, Antonio

Verderame, Francesco

Mazzi, Cristina

Marchetti, Fabiana

Kinspergher, Stefania

Occhipinti, Denis

Corte, Carminia Maria Della

Piscazzi, Daniele

Gilli, Marina

Bria, Emilio

Caffo, Orazio

Gori, Stefania
License Information

Text and Data Mining valid from 2025-07-12

Version of Record valid from 2025-07-12
More Information

Article History

Received: 9 March 2025

Accepted: 21 June 2025

First Online: 12 July 2025

Declarations

:

: Alessandro Inno: honoraria/advisory board roles from Amgen, Astra Zeneca, Merck Sharp-Dome, Novartis, Roche. Carlo Genova: honoraria/advisory board roles from Amgen, Astra Zeneca, Bristol-Myers-Squibb, Daiichi-Sankyo, Eli Lilly, Merck-Sharp-Dohme, Novartis, Pierre Fabre, Regeneron, Roche, Takeda. The other authors declare no conflicts of interest.

Document is current

Any future updates will be listed below